Compare Liberty Global Ltd Class C (LBTYK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Global Ltd Class C vs Merck & Co., Inc. — how do they compare? Liberty Global Ltd Class C trades at $9.98 (market cap $3.47B), while Merck & Co., Inc. trades at $124.78 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 88.5× Liberty Global Ltd Class C's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals.
| LBTYK | MRK | |
|---|---|---|
Market Cap | $3.47B | $307.25B |
Sector | Technology | Health |
52-Week High | $12.67 | $129.52 |
52-Week Low | $10.00 | $77.60 |
Enterprise Value | $10.75B | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LBTYK trades at $9.995, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion for 2025, though revenue grew to $4.88 billion. Recent news highlights strategic moves, including the planned 2027 Amsterdam listing of Ziggo Group. Analyst consensus is strongly positive, with 69% recommending Buy.
The outlook hinges on execution of the Ziggo Group spin-off, a potential value catalyst. However, persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. The stock offers a deep value opportunity if management delivers on restructuring, but operational turnaround is critical for sustained recovery.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
